Enterome’s OncoMimic technology allows the overcoming of immune tolerance against cancer cells, with broad applicability against solid tumor via an off-the-shelf, easy to manufacture technology. Enterome’s potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect oractions of Tumor Associated Antigens to induce a potent, endogenous CD8 T cell response. The company’s most advanced programs are in Phase 2 clinical trials in hard-to-treat tumors such as glioblastoma, adrenal malignancies and colorectal cancer.

Therapeutics

Life Sciences

Health Care

Biotechnology

Enterome

Belichard Pierre

Lucie Rouch

Joao G. Magalhaes

Pierre Sahakian

Marie-Laure Bouttier

Joel Richard, PhD, HDR

Jean-Michel Paillarse

Jan Fagerberg

Christelle Dumoussaud

The Clinical Development team at Enterome is responsible for overseeing and managing the progression of Enterome’s innovative drug candidates through the clinical trial phases. This includes coordinating clinical trial operations, developing project timelines, managing resources, and ensuring compliance with regulatory standards to advance the OncoMimic technology from Phase 2 trials through to potential market approval.

Clinical Development

Research and Development

Leadership Team

��

Clinical Development

About

Team members

Other teams at Enterome

Research and Development

Leadership Team

��������

Clinical Development

About

Team members

Other teams at Enterome

Research and Development

Leadership Team

��